Additionally, without using tumor cells, we treated mice with a T cell chemokine – C-X-C motif chemokine ligand 10 (CXCL10) (Griffith et al., 2014), or named as interferon-inducible protein-10 (IP-10) – intrabronchially for 2 hr, as illustrated in Figure 1—figure supplement 10A, and found that the proportion of CTLs in FPM-treated mice (about 8%) significantly decreased compared with that of the PBS group (about 18%; Figure 1—figure supplement 10B). Here, CXCL10 is linked to neoplasm.